Bulletin from the Annual General Meeting in Oncopeptides AB (publ) Regulatory
May 22, 2025
Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed
Read more
Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled
May 20, 2025
Stockholm, May 20, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first patient has been enrolled in its new real-world evidence study, evaluating the use of Pepaxti in routine clinical settings across Spain
Read more
Oncopeptides publishes Q1 report 2025 Regulatory
May 15, 2025
Stockholm – May 15, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025
Read more
Invitation to presentation of the Q1 report 2025
May 13, 2025
Stockholm – May 13, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025
Read more
Oncopeptides publishes the 2024 Annual Report Regulatory
April 28, 2025
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2024 Annual Report has been published
Read more
New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients
April 16, 2025
Stockholm, April 16, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting
Read more
Annual General Meeting in Oncopeptides AB (publ) Regulatory
April 16, 2025
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m. Registration for attendees will commence at 09.30 a.m
Read more
U.S. Food and Drug Administration removes clinical hold of Oncopeptides’ pipeline drug OPD5
April 1, 2025
Stockholm – April 1, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5
Read more
Oncopeptides receives first order of Pepaxti in Italy
March 11, 2025
Stockholm – March 11, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has received the first order of its flagship drug Pepaxti (melflufen) from an Italian hospital
Read more
Number of shares and votes in Oncopeptides Regulatory
February 28, 2025
Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 10,572,577 new class C shares. The shares are issued by virtue of the Annual General Meetings’ resolution on 31 May 2024 on authorisation for the Board of Directors to resolve on issue of class C shares to enable delivery of shares to participants under the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024 as well as other outstanding shareholder programs for members of the Board of Directors
Read more